BridgePort Financial Solutions LLC Raises Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• BridgePort Financial Solutions LLC significantly increased its stake in Gilead Sciences by 71.0% in Q2, bringing its total shares to 7,054, valued at $782,000.
• Several hedge funds, including Vanguard and Price T Rowe Associates, have also raised their stakes in Gilead, contributing to the fact that approximately 83.67% of the stock is owned by institutional investors.
• Gilead Sciences reported an EPS of $2.01 for Q2, surpassing analyst expectations, and the company has recently set a FY 2025 guidance of 7.950-8.250 EPS.

BridgePort Financial Solutions LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,054 shares of the biopharmaceutical company's stock after buying an additional 2,928 shares during the period. BridgePort Financial Solutions LLC's holdings in Gilead Sciences were worth $782,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after buying an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Gilead Sciences by 12.5% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company's stock worth $414,948,000 after purchasing an additional 417,237 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $117.17.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $112.69 on Friday. The company's fifty day simple moving average is $114.34 and its 200-day simple moving average is $109.94. Gilead Sciences, Inc. has a 52 week low of $83.98 and a 52 week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.